Korean J Neurotrauma.  2016 Oct;12(2):123-127. 10.13004/kjnt.2016.12.2.123.

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single

• Shin CJ
• Kim S
• Choi CS
• Shin HC
• Kwon YJ

• KMID: 2356785
• DOI: http://doi.org/10.13004/kjnt.2016.12.2.123

Abstract

OBJECTIVE
Bisphosphonate, a typical bone resorption inhibitor, is an important first-line drug for treating osteoporosis. Recent studies show a novel paradigm in stimulating bone formation. Teriparatide, which is composed of recombinant human parathyroid hormone, stimulates osteoblasts and induces bone regeneration. Bone mineral density (BMD) that was used before and after the treatment with anti-osteoporosis drug was compared for the effectiveness in therapy between a combination of teriparatide and selective estrogen receptor modulator (SERM), and bisphosphonate.
METHODS
We retrospectively reviewed the outcomes of 85 postmenopausal women who were concurrently diagnosed with osteoporosis and spinal compression fracture between November 2008 and January 2015. The targeted group were treated with teriparatide and SERM (TS group, n=26) and bisphosphonate (B group, n=59).
RESULTS
In both groups, BMD of femur neck was not improved after the medication. In the TS group, on the other hand the BMD and T-score of lumbar spine has significantly improved. BMD ratio of lumbar spine was prominently higher than those of TS group.
CONCLUSION
The combination therapy of teriparatide and SERM was very effective in treating the lumbar spine, compared to that of bisphosphonate. Although the period of teriparatide treatment has been relatively short, the preventive effects of compression fracture were considerable. Thus, combination therapy of teriparatide and SERM is highly recommended for patients who are concerned with spinal compression fracture from osteoporosis.

Keyword

Postmenopause; Osteoporosis; Teriparatide; Selective estrogen receptor modulator

MeSH Terms

Bone Density
Bone Regeneration
Bone Resorption
Female
Femur Neck
Fractures, Compression*
Hand
Humans
Osteoblasts
Osteogenesis
Osteoporosis*
Parathyroid Hormone
Postmenopause
Raloxifene Hydrochloride*
Retrospective Studies
Selective Estrogen Receptor Modulators
Spine
Teriparatide*
Parathyroid Hormone
Raloxifene Hydrochloride
Selective Estrogen Receptor Modulators
Teriparatide

Reference

1. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20:962–970. PMID: 15883636.

2. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013; 52:360–365. PMID: 23072919.

3. Cho PG, Ji GY, Shin DA, Ha Y, Yoon DH, Kim KN. An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J. [epub ahead of print December 10, 2015]. DOI: 10.1007/s00586-015-4342-y.

4. Collinge C, Favela J. Use of teriparatide in osteoporotic fracture patients. Injury. 2016; 47(Suppl 1):S36–S38.

5. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164:2024–2030. PMID: 15477438.

6. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18:18–23. PMID: 12510801.

7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434–1441. PMID: 11346808.

8. Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, et al. Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis. Bone. 2014; 66:26–30. PMID: 24909538.

9. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23:1591–1600. PMID: 18505369.

10. Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int. 2014; 25:1945–1951. PMID: 24760244.